Condition
Pancreatogenic Diabetes Mellitus
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
Early P 1 (1)
Trial Status
Completed1
Enrolling By Invitation1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07503028Early Phase 1Enrolling By Invitation
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
NCT06406439Not ApplicableCompleted
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
NCT04129424Not ApplicableUnknown
Preliminary Exploration on the Operational Standards of Insulin Pump Installation in Diabetes Clinic in China
Showing all 3 trials